Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text

Medicine, Hematology, Pharmacology +17

Analysis of apoptosis by propidium iodide staining and flow cytometry

Carlo Riccardi, Ildo Nicoletti · Nature Protocols · 2006 · 1.7K citations

Life Sciences, Cell Biology, Pathology +9

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

R. Eric Davis, Vu N. Ngo, Georg Lenz et al. · Nature · 2010 · 1.6K citations · Full text

Medicine, Hematology, Oncology +14

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Lee Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences · 2010 · 1.5K citations · Full text

Life Sciences, Immunology, Pharmacology +17

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman et al. · Journal of Clinical Oncology · 2012 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17